Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 3
2006 1
2008 2
2009 1
2010 5
2011 1
2012 5
2013 4
2014 3
2015 2
2016 5
2017 2
2018 11
2019 8
2020 10
2021 9
2022 7
2023 8
2024 12
2025 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

92 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.
Cheng Y, Spigel DR, Cho BC, Laktionov KK, Fang J, Chen Y, Zenke Y, Lee KH, Wang Q, Navarro A, Bernabe R, Buchmeier EL, Chang JW, Shiraishi Y, Sezgin Goksu S, Badzio A, Shi A, Daniel DB, Hoa NTT, Zemanova M, Mann H, Gowda H, Jiang H, Senan S; ADRIATIC Investigators. Cheng Y, et al. N Engl J Med. 2024 Oct 10;391(14):1313-1327. doi: 10.1056/NEJMoa2404873. Epub 2024 Sep 13. N Engl J Med. 2024. PMID: 39268857 Clinical Trial.
MET alterations in NSCLC-Current Perspectives and Future Challenges.
Remon J, Hendriks LEL, Mountzios G, García-Campelo R, Saw SPL, Uprety D, Recondo G, Villacampa G, Reck M. Remon J, et al. Among authors: uprety d. J Thorac Oncol. 2023 Apr;18(4):419-435. doi: 10.1016/j.jtho.2022.10.015. Epub 2022 Oct 29. J Thorac Oncol. 2023. PMID: 36441095 Free article. Review.
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfeld C, Nagasaka M, Felip E, Yang N, Velcheti V, Lu S, Kao S, Dooms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC; TRIDENT-1 Investigators. Drilon A, et al. N Engl J Med. 2024 Jan 11;390(2):118-131. doi: 10.1056/NEJMoa2302299. N Engl J Med. 2024. PMID: 38197815 Free PMC article. Clinical Trial.
Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study.
Cortazar FB, Kibbelaar ZA, Glezerman IG, Abudayyeh A, Mamlouk O, Motwani SS, Murakami N, Herrmann SM, Manohar S, Shirali AC, Kitchlu A, Shirazian S, Assal A, Vijayan A, Renaghan AD, Ortiz-Melo DI, Rangarajan S, Malik AB, Hogan JJ, Dinh AR, Shin DS, Marrone KA, Mithani Z, Johnson DB, Hosseini A, Uprety D, Sharma S, Gupta S, Reynolds KL, Sise ME, Leaf DE. Cortazar FB, et al. Among authors: uprety d. J Am Soc Nephrol. 2020 Feb;31(2):435-446. doi: 10.1681/ASN.2019070676. Epub 2020 Jan 2. J Am Soc Nephrol. 2020. PMID: 31896554 Free PMC article.
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.
Smit EF, Felip E, Uprety D, Nagasaka M, Nakagawa K, Paz-Ares Rodríguez L, Pacheco JM, Li BT, Planchard D, Baik C, Goto Y, Murakami H, Saltos A, Pereira K, Taguchi A, Cheng Y, Yan Q, Feng W, Tsuchihashi Z, Jänne PA. Smit EF, et al. Among authors: uprety d. Lancet Oncol. 2024 Apr;25(4):439-454. doi: 10.1016/S1470-2045(24)00064-0. Lancet Oncol. 2024. PMID: 38547891 Clinical Trial.
50 Years of Progress in NSCLC: A New Fellow's Guide in the Clinic.
Naidoo J, Niroula A, Uprety D, Smeltzer M, Geissen N, Osarogiagbon RU, Mino-Kenudson M, Yatabe Y, Higgins K, Desai A, Reckamp KL, Lin JJ, Liu SV, Hegi-Johnson Franzcr F, Seetharamu N, Harpole D, Edelman MJ; IASLC Communications Committee. Naidoo J, et al. Among authors: uprety d. J Thorac Oncol. 2025 Oct;20(10):1392-1422. doi: 10.1016/j.jtho.2025.06.028. Epub 2025 Jul 3. J Thorac Oncol. 2025. PMID: 40617395 Review.
Lung Cancer in Nepal.
Shilpakar R, Paudel BD, Sharma R, Silwal SR, Sapkota R, Shrestha P, Dulal S, Piya MK, Tuladhar SM, Neupane P, Dhimal M, Niroula A, Uprety D. Shilpakar R, et al. Among authors: uprety d. J Thorac Oncol. 2022 Jan;17(1):22-29. doi: 10.1016/j.jtho.2021.10.020. J Thorac Oncol. 2022. PMID: 34930608 Free article. No abstract available.
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.
Borghaei H, de Marinis F, Dumoulin D, Reynolds C, Theelen WSME, Percent I, Gutierrez Calderon V, Johnson ML, Madroszyk-Flandin A, Garon EB, He K, Planchard D, Reck M, Popat S, Herbst RS, Leal TA, Shazer RL, Yan X, Harrigan R, Peters S; SAPPHIRE Investigators. Borghaei H, et al. Ann Oncol. 2024 Jan;35(1):66-76. doi: 10.1016/j.annonc.2023.10.004. Epub 2023 Oct 20. Ann Oncol. 2024. PMID: 37866811 Free article. Clinical Trial.
ABIM Maintenance of Certification-Reply.
Uprety D, West HJ. Uprety D, et al. JAMA. 2024 Jan 16;331(3):261-262. doi: 10.1001/jama.2023.24100. JAMA. 2024. PMID: 38113138 No abstract available.
92 results